(Pfizer) Pfizer Inc. has announced that its novel Covid-19 antiviral drug candidate PAXLOVID reduces the risk of death or hospitalization by 89%.
In an interim study, Pfizer found that no deaths occurred in patients who were treated with PAXLOVID through day 28, compared to 10 deaths on patients administered with placebo.
Pfizer now says it will stop further enrollments into the clinical study following high efficacies reported in the latest trials. The company will submit the data to the US FDA for emergency use authorization as soon as possible.
If approved, Pfizer’s oral treatment will be the first of its kind as a SARS-CoV-2-3CL protease inhibitor. The treatment could be used to reduce the severity of Covid illness and also reduce the chances of an infection after exposure.
PFE: NYSE is up +11.49% on premarket.
